scholarly journals Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32(4):507-523.

Blood ◽  
2016 ◽  
Vol 128 (7) ◽  
pp. 883-883
Keyword(s):  
Acute Leukemia ◽  
Arabinosyl Cytosine

Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia

1985 ◽  
Vol 20 (2) ◽  
pp. 191-193 ◽  
Author(s):  
Emilio P. Alessandrino ◽  
Ester Orlandi ◽  
Ercole Brusamolino ◽  
Mario Lazzarino ◽  
Carlo Bernasconi
Keyword(s):  
Acute Leukemia ◽  
Myelodysplastic Syndrome ◽  
Low Dose ◽  
Arabinosyl Cytosine

Therapeutic Activity of 4-Demethoxydauno-Rubicin (Idarubicin) in Adult Acute Leukemia

1983 ◽  
Vol 69 (6) ◽  
pp. 515-519 ◽  
Author(s):  
Giorgio Lambertenghi-Deliliers ◽  
Enrico Pogliani ◽  
Anna T. Maiolo ◽  
Maria A. Pacciarini ◽  
Elio E. Polli
Keyword(s):  
Bone Marrow ◽  
High Risk ◽  
Acute Leukemia ◽  
Cardiac Toxicity ◽  
Therapeutic Activity ◽  
Acute Leukemias ◽  
Cardiac Effects ◽  
Blast Cells ◽  
Sequential Combination ◽  
Arabinosyl Cytosine

Twenty-six patients affected by acute leukemia were treated with 4-demethoxydaunorubicin (idarubicin), a new anthracycline compound which in experimental leukemias showed an anti-tumoral activity superior to daunorubicin (DNR) and doxorubicin (DX), with a higher ratio of active to cardiotoxic doses. A group of 16 patients in relapse received idarubicin at a dosage of 5–6 mg/m2/day for 3 consecutive days; a second group of 6 relapsing and 4 previously untreated cases was treated with a sequential combination of idarubicin and arabinosyl cytosine. In all patients, a significant fall of bone marrow and peripheral blast cells was obtained. These preliminary results suggest that idarubicin has a therapeutic activity against human acute leukemias usually responsive to DNR or DX. The duration of myelosuppression varied from 7 to 50 days, leading in some cases to a high risk of infections. As regards other toxic effects (gastrointestinal, hepatic and acute cardiac toxicity, alopecia), idarubicin appears to be, in our experience, a well-tolerated drug; however, it is too early to comment on delayed cardiac effects.

Combinations of arabinosyl cytosine and 6-thioguanine for treatment of adults with acute leukemia

1975 ◽  
Vol 1 (1) ◽  
pp. 29-35 ◽  
Author(s):  
Gerald P. Bodey ◽  
Emil J. Freireich ◽  
Kenneth B. McCredie ◽  
Victorio Rodriguez ◽  
M. Andrew Burgess ◽  
...  
Keyword(s):  
Acute Leukemia ◽  
Arabinosyl Cytosine
Sign in / Sign up

Export Citation Format

Share Document